Eric Lawitz
Impact in
- Hepatology top 0.01%
- Hepatitis C virus research
- Liver physiology and pathology
- Liver Disease and Transplantation
- Epidemiology top 0.1%
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
Papers in
- Hepatology 256
- Hepatitis C virus research 237
- Liver Disease and Transplantation 10
- Liver Diseases and Immunity 9
- Epidemiology 113
- Liver Disease Diagnosis and Treatment 110
- Hepatitis B Virus Studies 3
- Co-authors
- John G. McHutchison (43 shared papers)Fred F Poordad (34 shared papers)Stefan Zeuzem (19 shared papers)Maribel Rodriguez‐Torres (28 shared papers)Rohit Seth Loomba (28 shared papers)Stuart C. Gordon (27 shared papers)Bruce R. Bacon (17 shared papers)Arun Jayant Sanyal (26 shared papers)
- Journals
- Journal of Hepatology (90 papers)Gastroenterology (43 papers)Hepatology (35 papers)New England Journal of Medicine (18 papers)Clinical Gastroenterology and Hepatology (13 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Eric Lawitz
350 papers receiving 33.6k citations
Eric Lawitz's Hit Papers
Peers
Comparison fields: 5 of 140
- Hepatology 22.4k
- Epidemiology 7.3k
- Cancer Research 1.2k
- Pharmacology 369
- Immunology 645
Countries citing papers authored by Eric Lawitz
This map shows the geographic impact of Eric Lawitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Lawitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Lawitz more than expected).
Fields of papers citing papers by Eric Lawitz
This network shows the impact of papers produced by Eric Lawitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Lawitz. The network helps show where Eric Lawitz may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Lawitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 371 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Treatment of HCV Infection by Targeting MicroRNA Hit paper breakdown → | 2013 | 1871 |
| 2 | Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection Hit paper breakdown → | 2013 | 1503 |
| 3 | Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection Hit paper breakdown → | 2011 | 1341 |
| 4 | Telaprevir for Retreatment of HCV Infection Hit paper breakdown → | 2011 | 1270 |
| 5 | Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection Hit paper breakdown → | 2014 | 1121 |
| 6 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Hit paper breakdown → | 2019 | 1078 |
| 7 | Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection Hit paper breakdown → | 2009 | 1002 |
| 8 | Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis Hit paper breakdown → | 2014 | 980 |
| 9 | Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection Hit paper breakdown → | 2014 | 972 |
| 10 | Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options Hit paper breakdown → | 2013 | 907 |
| 11 | Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection Hit paper breakdown → | 2015 | 699 |
| 12 | Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis Hit paper breakdown → | 2015 | 661 |
| 13 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Hit paper breakdown → | 2014 | 659 |
| 14 | Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis Hit paper breakdown → | 2024 | 622 |
| 15 | Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus Hit paper breakdown → | 2010 | 609 |
| 16 | All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study Hit paper breakdown → | 2015 | 572 |
| 17 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Hit paper breakdown → | 2010 | 570 |
| 18 | Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1 Hit paper breakdown → | 2012 | 515 |
| 19 | The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial Hit paper breakdown → | 2017 | 483 |
| 20 | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Hit paper breakdown → | 2013 | 480 |
About Eric Lawitz
Eric Lawitz is a scholar working on Hepatology, Epidemiology, Pharmacology, Pediatrics, Perinatology and Child Health and Genetics, having authored 371 papers that have together received 34.8k indexed citations. Recurring topics across this work include Hepatitis C virus research (237 papers), Liver Disease Diagnosis and Treatment (110 papers), Liver Disease and Transplantation (10 papers), Pharmacogenetics and Drug Metabolism (9 papers), Liver Diseases and Immunity (9 papers), Pharmaceutical studies and practices (4 papers), RNA Interference and Gene Delivery (4 papers) and Hepatitis B Virus Studies (3 papers). The work is most often cited by research in Hepatology (22.4k citations), Epidemiology (7.3k citations), Cancer Research (1.2k citations), Pharmacology (369 citations) and Immunology (645 citations). Eric Lawitz has collaborated with scholars based in United States, France and Germany. Frequent co-authors include John G. McHutchison, Fred F Poordad, Stefan Zeuzem, Maribel Rodriguez‐Torres, Rohit Seth Loomba, Stuart C. Gordon, Bruce R. Bacon, Arun Jayant Sanyal, Clifford A. Brass and Janice K. Albrecht. Their work appears in journals such as Journal of Hepatology, Gastroenterology, Hepatology, New England Journal of Medicine and Clinical Gastroenterology and Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.